



REPORTED IHC / FISH / MOLECULAR PROFILING REQUEST FORM

FOR HSL-AD LABORATORY USE ONLY

MATERIAL RECEIVED: _____

HSL-AD NUMBER: _____

DATE RECEIVED & INITIALS: _____

PATIENT / SAMPLE DETAILS

SURNAME: _____

SURGICAL ID: _____ BLOCK ID: _____

FORENAME: _____

BODY SITE: _____

DOB: _____

TUMOUR TYPE: _____

GENDER: F M DIFFERENT AT BIRTH

PRIMARY METASTATIC

REQUESTING LABORATORY/HOSPITAL & INVOICING DETAILS

CONSULTANT: _____

INVOICING DETAILS (if different)

ADDRESS: _____

CONTACT NAME: _____

ORGANISATION: _____

ADDRESS: _____

PHONE: _____

EMAIL: _____

PO NUMBER: _____

REPORTED IHC/FISH/MOLECULAR TESTS REQUESTED

BREAST IHC	GASTRIC IHC	NSCLC / LUNG IHC	FISH		
Her-2* If Her-2 Negative reflex to PD-L1** ER PR	Her-2* If Her-2 Negative reflex to PD-L1**	ALK* ROS1* Her-2*	HER2 (ERBB2) HER2 (ERBB2) Breast MYC Amp	Lymphoma BCL2 BCL6 MYC*** IRF4/DUSP22 CCND1*** MALT1 IGH	Sarcoma CDK4 DDIT3 EWSR1 MDM2 PDGFB
MMR IHC	MELANOMA IHC	PAN CANCER IHC	NSCLC / Lung ALK ROS1 MET Amp RET	Melanoma Melanoma	
MMR	BRAF V600E	Her-2* p16	Head & Neck ETV6/NTRK3 MAML2 NUTM MYB	Pan Cancer NTRK1-3 FGFR1 Amp FGFR2 Amp FGFR2 Rearrangement	
PD-L1 IHC			MOLECULAR PROFILING		
22C3 (Pembrolizumab) Breast (TNBC, CPS) Cervical (CPS) Head & Neck (CPS) Lung (NSCLC, TPS) Oesophageal/GOJ (CPS) Urothelial (CPS) Other (CPS) Other (TPS)	SP142 (Atezolizumab) Breast (TNBC, IC) Lung (NSCLC, IC) Urothelial (IC) Other (IC)	28-8 (Nivolumab) Gastric/GOJ (CPS) Head & Neck (TPS) Melanoma (TPS) Oesophageal (SCC, TPS) Urothelial (TPS) Other (CPS) Other (TPS)	HPV HPV Genotype Profiling (FFPE) Comprehensive Profiling for High & Low Risk HPV Genotypes by DNA PCR.		
			BREAST Prosigna NICE Approved Breast Cancer Prognostic Gene Signature Assay - Testing on excision specimen only, block essential. - This test is only performed for ER positive, Her-2 negative, lymph node negative patients.		

*Automatic confirmation by FISH for 2+ (Her-2) and weak/strong positive (ALK, ROS1) cases and as required.
**Reflex to PD-L1 testing for Her-2 negative Breast adenocarcinoma (Agilent PharmDx 22C3 and Roche SP142).
Reflex to PD-L1 testing for Her-2 negative GOJ adenocarcinoma (Agilent PharmDx 22C3 and 28-8).
***All CCND1 and MYC FISH requests will be performed using breakapart and fusion probes. Automatic reflex to extended MYC FISH panel (IGK, IGL, MYC::BCL6) as required.